Joo Young Na

Joo Young Na

Auto-generated profile, based on publicly available information

Joo Young Na

Pharmacoanalytical Shared Resource, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
CLChunjie Li
Chunjie Li
ANAnne Mary Noonan
Anne Mary Noonan
JHJohn Hays
John Hays
SRSameek Roychowdhury
Sameek Roychowdhury
PMPannaga Malalur
Pannaga Malalur
NJNing Jin
Ning Jin
Purpose: Colorectal cancer is the second leading cause of cancer-related mortality in the United States. Chemotherapies based on 5-fluorouracil (5-FU), when combined with targeted agents, remain the standard of care for patients with metastatic or locally advanced disease. New treatment strategies are needed for patients with metastatic colorectal cancer with microsatellite stable disease. Preclinical studies have shown that riluzole, an oral medicine for amyotrophic lateral sclerosis, inhibits glutamate release and synergizes with 5-fluorouracil to reduce cell viability in colorectal cancer cell lines. Patients and Methods: In this single-arm, phase I trial of riluzole in combination with mFOLFOX6/bevacizumab for patients with metastatic colorectal cancer, the riluzole dose started at 50 mg twice daily, escalating to 100 mg twice daily or de-escalating to 50 mg once daily. Patients received riluzole for 16 weeks in combination with mFOLFOX6/bevacizumab for eight cycles. Patients then either continued mFOLFOX6/bevacizumab or switched therapies. Results: Twelve of the 14 patients enrolled were evaluable. All patients had previously received FOLFOX, and five patients (41.7%) showed disease resistance to it. Two patients obtained partial responses, nine had stable disease, and one had progressive disease. The objective response rate was 16.7%, and the disease control rate was 91.7%. The median duration of response was 4.9 months (95% confidence interval, 1.6–9.8). Median progression-free survival and overall survival were 4.89 and 12.98 months, respectively. Conclusions: Our study showed that riluzole plus mFOLFOX6/bevacizumab is well tolerated in patients with metastatic colorectal cancer and may have clinical activity in patients whose disease is resistant to FOLFOX.

10 October 2022 in Clinical and Translational Science
Verified
Journal Article
Open access
JNJoo Young Na
Joo Young Na
DYDeok Yong Yoon
Deok Yong Yoon
HYHyounggyoon Yoo
Hyounggyoon Yoo
SLSeungHwan Lee
SeungHwan Lee
KYKyung‐Sang Yu
Kyung‐Sang Yu
JOJaeseong Oh
Jaeseong Oh
This study aimed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of vutiglabridin, a potential anti‐obesity treatment under development, for the first time in humans. A randomized, placebo‐controlled, single‐ and multiple‐ascending dose study (SAD and MAD, respectively) was performed in healthy Koreans and Whites. Subjects randomly received a single oral dose of 30–720 mg vutiglabridin or placebo at a ratio of 8:2 in the SAD study or 240–480 mg vutiglabridin or placebo once daily for 14 days in the MAD study. Food effect was also evaluated in 240 mg single dose group. Pharmacokinetics were evaluated through plasma concentrations, and pharmacodynamic biomarkers related to obesity or inflammation were analyzed. Safety and tolerability were assessed throughout the study. Single and multiple doses of vutiglabridin were generally well‐tolerated. The pharmacokinetic parameters show less than dose‐proportionality increase, and plasma concentrations increased more than two‐fold after multiple administrations. The mean half‐life of Koreans and Whites in the MAD study was 110 and 73 h, respectively. The systemic exposure of vutiglabridin was significantly increased when taken with a high‐fat meal, and the systemic exposure was lower in Whites than in Koreans. Vutiglabridin was well‐tolerated in healthy Koreans and Whites. The plasma concentration increased less than the dose‐proportionality manner. These results justify further investigation of vutiglabridin in patients with obesity.

19 March 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
KHKi Young Huh
Ki Young Huh
SHSejung Hwang
Sejung Hwang
JNJoo Young Na
Joo Young Na
KYKyung‐Sang Yu
Kyung‐Sang Yu
IJIn‐Jin Jang
In‐Jin Jang
SYSeonghae Yoon
Seonghae Yoon
Genetic variants affect drug responses, making pre‐emptive genotyping crucial for averting serious adverse events (SAEs) and treatment failure. However, assessing the benefits of pre‐emptive genotyping based on genetic distribution, drug exposure, and demographics is challenging. This study aimed to estimate the population‐level benefits of pre‐emptive genotyping in the Korean population using nationwide cohort data. We reviewed actionable gene‐drug combinations recommended by both the Clinical Pharmacogenomics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) as of February 2022, identifying high‐risk phenotypes. We collected reported risk reduction from genotyping and standardized it into population attributable risks. Healthcare reimbursement costs for SAEs and treatment failures were obtained from the Health Insurance Review and Assessment Service Statistics in 2021. The benefits of pre‐emptive genotyping for a specific group were determined by multiplying drug exposure from nationwide cohort data by individual genotyping benefits. We identified 31 gene‐drug‐event pairs, with CYP2D6 and CYP2C19 demonstrating the greatest benefits for both male and female patients. Individuals aged 65–70 years had the highest individual benefit from pre‐emptive genotyping, with $84.40 for men and $100.90 for women. Pre‐emptive genotyping, particularly for CYP2D6 and CYP2C19, can provide substantial benefits.

7 October 2024 in Cancer Science
Verified
Journal Article
Open access
JNJoo Young Na
Joo Young Na
JJJuyeun Jeon
Juyeun Jeon
KHKi Young Huh
Ki Young Huh
KYKyung‐Sang Yu
Kyung‐Sang Yu
SLSangmi Lee
Sangmi Lee
JOJaeseong Oh
Jaeseong Oh
ABL001/CTX‐009 is a bispecific antibody targeting delta‐like ligand‐4 and vascular endothelial growth factor A. In this study, we developed a population pharmacokinetic (PK) model of ABL001/CTX‐009 in patients with solid tumors. A total of 712 plasma concentrations from 30 patients with relapsed or refractory solid tumors were collected from a phase 1 study (NCT03292783). A population PK model was developed using a nonlinear mixed‐effect method and was evaluated by graphical and numerical methods. Using the model, the steady‐state concentrations were simulated to compare weight‐based and fixed‐dose regimens and to find optimal dosing intervals. The PK of ABL001/CTX‐009 was well described by a two‐compartment model with a parallel first‐order and Michaelis–Menten elimination kinetics. Body weight was selected as a significant covariate on V1. Model evaluation results suggested that the model was adequate and robust with good precision. Simulations after administrations of fixed or weight‐based doses showed similar plasma concentrations. Additionally, 10 mg/kg for every other week and 15 mg/kg for every three‐week administration showed comparable plasma concentrations. In conclusion, the model well described the plasma concentrations of ABL001/CTX‐009 in patients with solid tumors. The simulation suggested that weight‐based dose and fixed dose can provide equivalent systemic exposure.


3 June 2025
Verified
Other
Open access
CLChunjie Li
Chunjie Li
ANAnne Mary Noonan
Anne Mary Noonan
JHJohn Hays
John Hays
SRSameek Roychowdhury
Sameek Roychowdhury
PMPannaga Malalur
Pannaga Malalur
NJNing Jin
Ning Jin
Supplementary Figure 1 from Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer: A Phase I Clinical Trial